Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

When to use apremilast and biologics and how to deal with vascular involvement were some of the main areas to be updated in ...

The guidelines include disease-specific recommendations screening, monitoring disease progression, and treatment options for ILD.

Different vasoactive vasodilating drugs were associated with protective effects depending on patients' vasculopathy, but ...

We focus on looks and performance, but muscle’s metabolic, anti-inflammatory, and disease-resisting properties make it an ...

Patients treated with upadacitinib have lower rates of lung function decline with no significant adverse events.

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

AMA’s new president argues against federal budget cuts at the group’s annual policy meeting, where physicians oppose RFK Jr’s ...

The impact of witnessing unprofessional behavior without adequate response mechanisms extends far beyond individual cases.

Genetic research, single-cell RNA sequencing, and spatial transcriptomics suggest that a prolonged anagen stage in the ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...